Stem Cell-Based Retinal Implant May Halt Progression of Dry AMD


A stem cell-based implant has been shown in a phase 1/2a trial to not only halt AMD disease progression but possibly improve vision.

Amir H. Kashani, MD, PhD

For patients with advanced dry age-related macular degeneration (AMD), an implant consisting of a layer of human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells has shown positive results in potentially stopping the progression of the condition—and even improving eyesight.

Led by Amir H. Kashani, MD, PhD, an assistant professor of clinical ophthalmology at the USC Roski Eye Institute, the team performed a preliminary assessment of the therapy’s efficacy. A single patient had improvement in visual acuity by 17 letters, and 2 patients had gains in visual function in fixation.

None of the patients showed evidence of progression in vision loss.

“This is the first human trial of this novel stem cell-based implant, which is designed to replace a single-cell layer that degenerates in patients with dry age-related macular degeneration,” Kashani, also the surgeon for the study said in a statement. “This implant has the potential to stop the progression of the disease or even improve patients’ vision. Proving its safety in humans is the first step in accomplishing that goal.”

The implant, dubbed the California Project to Cure Blindness—Retinal Pigment Epithelium 1 (CPCB-RPE1), was implanted in 4 patients total. The use of optical coherence tomography (OCT) revealed consistent changes with hESC-RPE and host photoreceptor integration, according to the team.

Kashani told MD Magazine that the idea behind the implant came from the need for treatments for an existing population of patients with dry AMD, the more common form of the disease. “It can cause severe vision loss, legal blindness, or worse, and it's actually one of the leading causes of vision loss in the Western world,” he said.

“There's no treatment for those people because they go blind because a single cell layer in their eye—the RPE—essentially degenerates,” Kashani said. “There is a lot of debate as to why that happens, but that's the ultimate result.”

Mark S. Humayun, MD, PhD, lead inventor of the implant, and director of the USC Institute for Biomedical Therapeutics, co-director of the USC Roski Eye Institute, said in a statement that these results show the implant is generally well-tolerated, and suggest that it could be used to help the estimated 1.7 million Americans with dry AMD.

The study, “A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration,” was published in Science Translational Medicine.

Related Videos
A panel of 3 experts on dry eye
A panel of 3 experts on ocular diseases and conditions
Viability of Elamipretide for Geographic Atrophy in Dry AMD | Image Credit: HCPLive
Advancing Elamipretide into Phase 3 ReNEW and ReGAIN Trials | Image Credit: HCPLive
Elamipretide in ReCLAIM-2 Trial | Image Credit: HCPLive
Hong-Uyen Hua, MD; Sruthi Arepalli, MD; and Peter Kaiser, MD
Kelly Nichols, OD; Laura Periman, MD; and Mile Brujic, OD
© 2024 MJH Life Sciences

All rights reserved.